Ixiaro by Valneva SE - Japanese encephalitis shot for serious travelers

Ixiaro, Valneva's inactivated Japanese encephalitis vaccine, targets long-stay and rural travelers in Asia and the Western Pacific. This product is driving the price of Valneva SE stock (ISIN FR0013280286).

Ixiaro by Valneva lands in the travel clinic fridge with a quiet click, the small beige box sitting next to yellow fever and rabies shots. A nurse rolls the vial gently between her fingers before drawing up the dose for a backpacker headed to rice fields in Vietnam.

Who Ixiaro is really for

Valneva developed Ixiaro as an inactivated vaccine against Japanese encephalitis, a mosquito-borne viral infection endemic in large parts of Asia and the Western Pacific. The shot is aimed at adults and children who spend longer periods outdoors in rural areas, especially near rice paddies and pig farms.

The company highlights that risk is highest for travelers staying at least one month or repeatedly visiting endemic regions, not for a quick city weekend. Infectious disease specialist Dr. Petra Zimmermann at a Swiss travel clinic often recommends Ixiaro to engineers on multi-month construction projects and NGO workers in monsoon-season field camps.

Dosing schedule and protection window

On Valneva's official product page, Ixiaro is presented as a two-dose series: the first injection on day 0, the second 28 days later. Full protection is typically reached about one week after the second dose, so clinics advise starting at least five weeks before departure to risk regions.

For adults aged 18 to 65 years who may need to extend protection, a booster dose can be considered after 12 to 24 months if exposure continues. In practice, travel physicians like Dr. Zimmermann often time the booster before a new rotation to rural Asia, when a client has a history of long stays near stagnant water.

Formulation and safety profile

On the official European product information sheet, Ixiaro is described as containing inactivated, purified Japanese encephalitis virus strain SA14-14-2 grown in Vero cells, with aluminum hydroxide as an adjuvant. The vaccine does not contain live virus and cannot cause the disease.

Typical side effects are local pain, redness or swelling at the injection site, and sometimes headache or mild fever, mostly resolving within a few days. Serious adverse events are rare, but clinics still keep patients under observation for at least 15 minutes after the shot, a cautious routine that travel physicians like Dr. Zimmermann apply across all injectable vaccines.

Regulatory approvals and indications

Ixiaro holds marketing authorization in the European Union and several other markets, with the US version marketed under the name Ixiaro as well but regulated via the Food and Drug Administration. The core indication is active immunization against Japanese encephalitis in persons aged 2 months and older who are at risk of exposure in endemic areas.

In many national guidelines, the vaccine is recommended specifically for travelers staying in endemic areas during the transmission season, especially in rural parts of South and Southeast Asia. It is not part of routine childhood schedules in Europe; instead, it appears as a niche entry in travel health recommendations, where doctors like Dr. Zimmermann screen itineraries for overnight stays near rice farming zones.

Position in Valneva's specialty vaccine line-up

Valneva positions Ixiaro as one of its key marketed products in the specialty vaccine segment, alongside other travel and endemic disease vaccines such as the chikungunya vaccine and candidate products for Lyme disease. In past investor presentations, CEO Thomas Lingelbach has pointed to Ixiaro as a stable revenue contributor, supported by recurring demand from travel clinics and military contracts.

The company emphasizes that Japanese encephalitis remains a public health concern in several Asian countries, and that global travel patterns require reliable protection options. For retail investors, Ixiaro is less visible than headline-grabbing COVID-19 projects, but still matters because it anchors the portfolio in a steady, risk-focused niche of travel medicine.

Pricing and access in key markets

In Germany, travel clinics typically charge between 100 and 140 euros for the two-dose Ixiaro series, including consultation and injection fees, according to published price ranges from major travel health centers. The pure vaccine cost often falls around 60 to 70 euros per dose, with variations by provider and region.

Many statutory health insurers in Germany do not routinely reimburse travel vaccines, so customers pay out of pocket, which makes transparent pricing crucial. In the United States, the cash price per dose can be higher, often above 200 dollars including clinic fees, and some private insurers only cover the shot when travel is work-related. That turns Ixiaro into a thoughtful purchase, weighed against trip length and exposure risk in mosquito-heavy rural areas.

Logistics, storage and clinic workflows

According to the official summary of product characteristics, Ixiaro must be stored in a refrigerator between 2 °C and 8 °C and not frozen. Clinics keep the boxes on middle shelves, away from freezing coils, and staff like nurse Jana carefully check lot numbers and expiry dates before each injection.

The vaccine is supplied as a suspension for injection in a pre-filled syringe or vial, which needs gentle shaking to obtain a uniform white suspension before administration. In practice, that means a short pause at the treatment room desk: Jana holds the syringe up to the light, taps it once, and confirms there are no visible particles aside from the expected faint cloudiness.

Who should not get Ixiaro

European regulatory documents list known hypersensitivity to the active substance or any excipients, including aluminum hydroxide, as a contraindication for Ixiaro. Persons who experienced a severe allergic reaction after a previous dose should not be re-vaccinated.

The summary also advises postponing vaccination in individuals with acute severe febrile illness, though minor infections do not necessarily require delay. Travel doctors like Dr. Zimmermann therefore reschedule clients with high fever or influenza-like symptoms, preferring a clear baseline before administering a vaccine intended for long-term protection on demanding trips.

Data on efficacy and real-world use

Clinical trial data published via regulatory authorities show that Ixiaro induces protective neutralizing antibody levels in the vast majority of vaccinated adults and children after the two-dose series. One pivotal study reported seroconversion rates above 95 percent in adult travelers, placing the vaccine among the more effective travel shots in routine practice.

Real-world observational studies from travel medicine centers confirm low rates of Japanese encephalitis in appropriately vaccinated cohorts, though absolute case numbers are small given the rarity of documented infections among Western travelers. For investors, those figures translate into a product that serves a precise but limited population, with growth more dependent on regional travel trends than mass immunization campaigns.

Competition and differentiation

Ixiaro competes with other Japanese encephalitis vaccines, including live attenuated options used in some endemic countries for routine childhood immunization. Valneva's edge lies in offering an inactivated, purified vaccine tailored to the regulatory standards and risk profile of travelers and military personnel from Europe and North America.

The absence of live virus and the data on immunogenicity after two doses help travel clinics justify the cost to clients who may be hesitant about additional shots before departure. At the same time, the need for a second dose and occasional boosters creates recurring appointment touchpoints, which clinicians like Dr. Zimmermann use to screen for other travel risks such as malaria, dengue or altitude sickness.

Operational impact for clinics and insurers

For travel clinics, stocking Ixiaro means allocating fridge space to a product with seasonal demand spikes, often climbing before summer and winter monsoon seasons when more travelers head into rural Asia. Clinic managers plan batch orders around expiry dates, since unused doses represent sunk costs in a niche segment where patient flow is harder to predict than for influenza shots.

Health insurers evaluate Ixiaro within broader travel vaccine packages, sometimes offering reimbursement only for employees on company-sponsored trips to endemic countries. That makes employer travel policies an indirect driver of Ixiaro uptake: corporate medical advisors decide whether engineers in Laos, agronomists in Cambodia or project managers in rural China should receive the vaccine as standard preparation when working in mosquito-prone settings.

Valneva SE stock context

From a stock perspective, Ixiaro represents a steady, specialized revenue stream in Valneva's portfolio, balancing more volatile research-stage projects in areas like Lyme disease and chikungunya. The Valneva SE stock trades on Euronext Paris in euros, and performance reflects a mix of these marketed travel vaccines and the firm's broader pipeline risks.

Key facts: Ixiaro by Valneva SE

• Product: Ixiaro
• Manufacturer: Valneva SE
• Category: B2B/Pro travel vaccine
• Market launch: First approvals in Europe and the US in late 2000s
• MSRP / Price: Roughly 60–70 EUR per dose in German travel clinics, higher in US markets
• Availability: Prescription-only via travel clinics, hospitals and occupational health services in Europe, North America and other selected regions
• Target group: Travelers and military personnel spending extended periods in rural endemic areas in Asia and the Western Pacific
• Highlight / USP: Inactivated, purified Japanese encephalitis vaccine tailored to stringent traveler-focused regulatory standards